Actuate Therapeutics, Inc., a biopharmaceutical company headquartered in Chicago and Fort Worth, Texas, announced plans for an underwritten public offering of its common stock. The company, trading on the NASDAQ under the symbol ACTU, focuses on developing therapies for challenging cancers by targeting glycogen synthase kinase-3 beta (GSK-3β). In the offering, Actuate intends to sell shares of common stock with underwriters having the option to purchase up to 15% additional shares at the public offering price. The completion and terms of the offering are contingent on market conditions, with no guarantees on finalization or size.